Provided by Tiger Trade Technology Pte. Ltd.

Entera Bio Ltd.

2.88
-0.0700-2.37%
Volume:215.03K
Turnover:616.74K
Market Cap:498.24M
PE:-8.14
High:2.94
Open:2.94
Low:2.80
Close:2.95
52wk High:4.20
52wk Low:0.9100
Shares:173.00M
Float Shares:138.87M
Volume Ratio:0.74
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3536
EPS(LYR):-0.2476
ROE:-138.92%
ROA:-45.98%
PB:68.57
PE(LYR):-11.63

Loading ...

Correction: Entera to Participate in Upcoming Fall Investor Conferences

GlobeNewswire
·
Aug 27

Entera Bio CEO Toledano Joins Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Aug 27

Entera Bio Files Form 3 for Chief Medical Officer Riccardo Paolo Camisasca

Reuters
·
Aug 21

Entera Bio Names Riccardo Paolo Camisasca Chief Medical Officer

Reuters
·
Aug 18

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

GlobeNewswire
·
Aug 18

Israel's Camtek Q2 Revenue Beats on Increased AI Compute Demand

Reuters
·
Aug 10

Israel's Perion Q2 Revenue Tops Estimates on Retail Media Growth

Reuters
·
Aug 10

Monday.com Q2 Revenue Rises as AI Focus Grows

Reuters
·
Aug 10

Plus500 H1 Revenue Rises to Three-Year High on Trading Income Growth

Reuters
·
Aug 10

Israel's Entera Bio Q2 Net Loss Widens

Reuters
·
Aug 08

Entera Bio Q2 EPS $(0.14) Misses $(0.08) Estimate

Benzinga Earnings
·
Aug 08

Entera Bio Ltd Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 08

Press Release: Entera Announces Second Quarter 2026 Financial Results and Business Updates

Dow Jones
·
Aug 08

Entera Bio Says Phase 2 Post-Hoc Analysis Supports Anabolic Effect of Oral EB613 in High-Risk Postmenopausal Osteoporosis Patients

Reuters
·
Aug 04

Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting

GlobeNewswire
·
Aug 04

Entera Bio Ltd Expected to Post a Loss of 8 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Entera Bio CEO Joins Canaccord Genuity Annual Growth Conference Fireside Chat

Reuters
·
Aug 01

NASDAQ Trade Halt Volatility Trading Pause at 09:57 Am

Reuters
·
Jul 27

Entera Bio Prices USD 275 Million Private Placement at USD 2.04 Per Share

Reuters
·
Jul 27

Entera Bio Leads Our Top 3 Penny Stocks To Consider

Simply Wall St.
·
Jul 22